Raymond W. Cohen
Mr. Cohen has served as Chief Executive Officer and member of the board of directors of Axonics since co-founding the company in October 2013. Mr. Cohen is an accredited public company director with over 40 years of experience in leading medical device companies and serving as a board member at a number of private and publicly traded life science companies.
From 2010 to 2012, he served as CEO of Vessix Vascular, a venture capital-backed renal denervation company that was acquired by Boston Scientific in November 2012. Previously, Mr. Cohen spent nearly a decade as Chairman and CEO of Nasdaq-listed Cardiac Science Inc., which was ranked as the fourth fastest growing company in the U.S. in 2004. Mr. Cohen currently serves as a Chairman of the board of BioVentrix Inc., a privately-held transcatheter ventricular restoration company focused on treating congestive heart failure patients.
From May 2006 to July 2021, Mr. Cohen served on the board of directors at BioLife Solutions (Nasdaq: BLFS) a developer and manufacturer of preservation media for regenerative medicine and for the last 8 years served as Chairman. From June 2013 to April 2020, Cohen served as an independent director, chair of the compensation committee and member of the audit and nominating committees of Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI). Mr. Cohen also previously served on the boards of two companies that were successfully sold in 2017: Zurich-based LifeWatch (LIFE.SW), sold to Biotelemetry (Nasdaq: BEAT); and Colorado-based Syncroness, Inc., a privately held contract engineering firm, sold to ALTEN Group, a multibillion-dollar French engineering services company.